Drugs / HTX-011B
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02762929 | May 2016 → Feb 2017 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02689258 | Feb 2016 → Mar 2017 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02504580 | Jul 2015 → Mar 2017 | — | Heron Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-09-08 | Heron Therapeutics | Results Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016 herontx.com ↗
There was a 29.5% reduction in pain as measured by SPI 0-24 (p=0.0035). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-09-08 | Heron Therapeutics | Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016 herontx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTX-011B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02504580 ↗ |
| Known as | HTX-011-56 | “HTX-011B is the final formulation studied (HTX-011-56), which was also included in subsequent Phase 2b and Phase 3 studies.” NCT02762929 ↗2“HTX-011B is the final formulation studied (HTX-011-56), which was also included in subsequent Phase 2b and Phase 3 studies.” NCT02504580 ↗ “HTX-011B is the final formulation studied (HTX-011-56), which was also included in subsequent Phase 2b and Phase 3 studies.” NCT02689258 ↗ |
| Route | Other | “HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.” NCT02504580 ↗ |